| Q57791602 | Q57791602 |
| Q57791685 | Q57791685 |
| Q87446801 | (123)I-mIBG scintigraphy: yet another risk stratifier for the heart failure toolbox! |
| Q22306358 | 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |
| Q22241919 | 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines |
| Q28087002 | 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of [...] |
| Q34677347 | 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contrib |
| Q46502909 | 2017 ISHNE-HRS expert consensus statement on ambulatory ECG and external cardiac monitoring/telemetry. |
| Q64972630 | 2019 Focused Update of the Guidelines of the Taiwan Society of Cardiology for the Diagnosis and Treatment of Heart Failure. |
| Q53324224 | A Shocking End to the Defibrillator as We Know It: Unmet Needs and the Case for a Stand-Alone Device that Uses Pacing Only to Treat the Risk of Life-Threatening Arrhythmias. |
| Q28082305 | A systematic review of ICD complications in randomised controlled trials versus registries: is our 'real-world' data an underestimation? |
| Q53431943 | ASNC/SNMMI Model Coverage Policy: Myocardial sympathetic innervation imaging: Iodine-123 meta-iodobenzylguanidine ((123)I-mIBG). |
| Q92150489 | Absence of left bundle branch block and blood urea nitrogen predict improvement in left ventricular ejection fraction in patients with cardiomyopathy and wearable cardioverter defibrillators |
| Q38665047 | Advances in implantable cardioverter defibrillator therapy |
| Q36627456 | Adverse Experiences With Implantable Defibrillators in Oregon Hospices |
| Q34233026 | Aggregate national experience with the wearable cardioverter-defibrillator: event rates, compliance, and survival |
| Q37668985 | Aldosterone Antagonists in ST Elevation Myocardial Infarction Patients with Low Left Ventricular Ejection Fraction: a Retrospective Study at Shahid Gangalal National Heart Centre, Bansbari, Kathmandu, Nepal |
| Q36634189 | Aldosterone blockade in post-acute myocardial infarction heart failure. |
| Q37066818 | Almanac 2011: Cardiac Arrhythmias and Pacing. The National Society Journals Present Selected Research that has Driven Recent Advances in Clinical Cardiology |
| Q38198026 | Angiotensin receptor antagonists to prevent sudden death in heart failure: does the dose matter? |
| Q37711369 | Application of ICD guidelines and indications in a community-based academic hospital: a case series-based discussion |
| Q38221964 | Arrhythmias in structural heart disease |
| Q46549329 | Arrhythmias in the coronary care unit |
| Q38605352 | Arrhythmic death and ICD implantation after myocardial infarction |
| Q38933864 | Arrhythmic risk stratification in heart failure: Time for the next step? |
| Q91719404 | Arrhythmic risk stratification in post-myocardial infarction patients with preserved ejection fraction: the PRESERVE EF study |
| Q64123930 | Association of the US Department of Justice Investigation of Implantable Cardioverter-Defibrillators and Devices Not Meeting the Medicare National Coverage Determination, 2007-2015 |
| Q31085565 | Atrial tachyarrhythmias in primary and secondary prevention ICD recipients: clinical and prognostic data |
| Q41101756 | Avoiding Untimely Implantable Cardioverter/Defibrillator Implantation by Intensified Heart Failure Therapy Optimization Supported by the Wearable Cardioverter/Defibrillator-The PROLONG Study. |
| Q48402146 | B-type natriuretic peptide levels predict event-free survival in patients with implantable cardioverter defibrillators |
| Q38007585 | Bayesian meta-analysis on medical devices: application to implantable cardioverter defibrillators. |
| Q38537344 | Beta-blocker, angiotensin-converting enzyme inhibitor/angiotensin receptor blocker, nitrate-hydralazine, diuretics, aldosterone antagonist, ivabradine, devices and digoxin (BANDAID(2) ): an evidence-based mnemonic for the treatment of systolic heart |
| Q57665132 | CSI position statement on management of heart failure in India |
| Q36269175 | Can microvolt T-wave alternans testing reduce unnecessary defibrillator implantation? |
| Q36383373 | Canadian Cardiovascular Society consensus conference recommendations on heart failure 2006: diagnosis and management |
| Q46444353 | Cardiac Sympathetic Denervation for Refractory Ventricular Arrhythmias. |
| Q85280193 | Cardiac arrhythmias--trials and tribulations |
| Q38063294 | Cardiac resynchronization therapy for prevention of heart failure events in elderly patients with left ventricular dysfunction |
| Q37129728 | Cardiac resynchronization therapy: which device to implant? |
| Q35959779 | Cardiovascular magnetic resonance characterization of peri-infarct zone remodeling following myocardial infarction |
| Q45255726 | Cardioverter defibrillator implantation without induction of ventricular fibrillation: a single-blind, non-inferiority, randomised controlled trial (SIMPLE). |
| Q44391421 | Cardioverter-defibrillator implantation and generator replacement in the octogenarian |
| Q36115163 | Carvedilol's antiarrhythmic properties: therapeutic implications in patients with left ventricular dysfunction. |
| Q38077438 | Causes and prevention of sudden cardiac death in the elderly |
| Q58282668 | Causes of death and re‐hospitalization in cardiogenic shock |
| Q35086463 | Changing nature of cardiac interventions in older adults |
| Q34089592 | Chronic Kidney Disease and Mortality in Implantable Cardioverter-Defibrillator Recipients |
| Q45073081 | Circumferential strain acquired by CMR early after acute myocardial infarction adds incremental predictive value to late gadolinium enhancement imaging to predict late myocardial remodeling and subsequent risk of sudden cardiac death |
| Q40366318 | Clinical Usefulness of a Mobile Application for the Appropriate Selection of the Antiarrhythmic Device in Heart Failure. |
| Q39646747 | Clinical application of heart rate variability after acute myocardial infarction |
| Q46352061 | Clinical criteria for predicting benefit of ICD/PM in post myocardial infarction patients: an AVID and CAST analysis |
| Q34357612 | Clinical markers of organ dysfunction associated with increased 1-year mortality post-implantable cardioverter defibrillator implantation |
| Q46336435 | Clinical neurocardiology defining the value of neuroscience-based cardiovascular therapeutics |
| Q44522422 | Clinical outcomes in patients with implantable cardioverter defibrillators and Sprint Fidelis leads |
| Q34730989 | Clinical practice of defibrillator implantation after myocardial infarction: impact of implant time: results from the PreSCD II registry |
| Q44521759 | Clinical trials update from the American College of Cardiology 2008: CARISMA, TRENDS, meta-analysis of Cox-2 studies, HAT, ON-TARGET, HYVET, ACCOMPLISH, MOMENTUM, PROTECT, HORIZON-HF and REVERSE. |
| Q37495281 | Clinical trials update from the American College of Cardiology 2009: ADMIRE-HF, PRIMA, STICH, REVERSE, IRIS, partial ventricular support, FIX-HF-5, vagal stimulation, REVIVAL-3, pre-RELAX-AHF, ACTIVE-A, HF-ACTION, JUPITER, AURORA, and OMEGA. |
| Q43238410 | Clinical trials update from the European Society of Cardiology Meeting 2009: AAA, RELY, PROTECT, ACTIVE-I, European CRT survey, German pre-SCD II registry, and MADIT-CRT. |
| Q36103185 | Combined resynchronisation and implantable defibrillator therapy in left ventricular dysfunction: Bayesian network meta-analysis of randomised controlled trials |
| Q30609810 | Comparing outcome of patients with coronary artery disease and dilated cardiomyopathy in ICD and CRT recipients: data from the German DEVICE-registry |
| Q36839832 | Complication risk with pulse generator change: implications when reacting to a device advisory or recall |
| Q37695408 | Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators |
| Q47635686 | Consensus statement of the European Heart Rhythm Association: updated recommendations for driving by patients with implantable cardioverter defibrillators |
| Q46708261 | Cost-effectiveness of implantable cardioverter-defibrillators in Brugada syndrome treatment |
| Q47121564 | Current Therapeutic Options for Heart Failure in Elderly Patients |
| Q38917517 | Current Treatment Strategies for Heart Failure: Role of Device Therapy and LV Reconstruction. |
| Q33936131 | Current and emerging antiarrhythmic drug therapy for ventricular tachycardia |
| Q37892372 | Current pacemaker and defibrillator therapy |
| Q37590478 | Current status of implantable cardioverter-defibrillator therapy in heart failure |
| Q38158220 | Deactivation of implantable cardioverter-defibrillators at end of life |
| Q30953069 | Defibrillator implantations for primary prevention in the United States: Inappropriate care or inadequate documentation: Insights from the National Cardiovascular Data ICD Registry |
| Q35139951 | Device therapies: new indications and future directions |
| Q37786642 | Device therapy for the management of cardiac tachyarrhythmias. |
| Q36723119 | Diagnosis and treatment of asymptomatic left ventricular systolic dysfunction after myocardial infarction |
| Q92298367 | Does stress echocardiography add incremental value to baseline ejection fraction for the early identification of candidates for implantable defibrillators? |
| Q46986132 | Does the Implantable Cardioverter-Defibrillator Benefit Vary With the Estimated Proportional Risk of Sudden Death in Heart Failure Patients? |
| Q35492836 | Driving restrictions after implantable cardioverter defibrillator implantation: an evidence-based approach |
| Q36167689 | Drug and drug-device therapy in heart failure patients in the post-COMET and SCD-HeFT era. |
| Q36858827 | Drug insight: aldosterone-receptor antagonists in heart failure--the journey continues |
| Q34830023 | ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology |
| Q55050673 | ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology |
| Q36913808 | Early risk of mortality after coronary artery revascularization in patients with left ventricular dysfunction and potential role of the wearable cardioverter defibrillator |
| Q37749822 | Early therapy following myocardial infarction: arguments for and against implantable cardioverter-defibrillators. |
| Q92716297 | Echocardiographic predictors of all-cause mortality in patients with left ventricular ejection fraction >35%: Value of guideline based assessment of diastolic dysfunction |
| Q41938010 | Effective and efficient use of implantable defibrillators: sometimes it's over when it's over |
| Q34237260 | Effectiveness of prophylactic implantation of cardioverter-defibrillators without cardiac resynchronization therapy in patients with ischaemic or non-ischaemic heart disease: a systematic review and meta-analysis |
| Q51285848 | Efficacy and safety of ICD therapy in a population of elderly patients treated with optimal background medication. |
| Q37100652 | Ejection fraction assessment and survival: an analysis of the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). |
| Q37684539 | Electroanatomic remodeling of the left stellate ganglion after myocardial infarction |
| Q36623124 | Electrocardiographic predictors of arrhythmic death. |
| Q45866944 | Emerging molecular therapies targeting myocardial infarction-related arrhythmias |
| Q27012843 | End points for comparative effectiveness research in heart failure |
| Q39902305 | Epicardial border zone overexpression of skeletal muscle sodium channel SkM1 normalizes activation, preserves conduction, and suppresses ventricular arrhythmia: an in silico, in vivo, in vitro study |
| Q36383698 | Epidemiology and stratification of risk for sudden cardiac death |
| Q26796261 | European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society |
| Q38571627 | European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. |
| Q46965886 | Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction |
| Q37204531 | Experience With the Wearable Cardioverter-Defibrillator in Patients at High Risk for Sudden Cardiac Death |
| Q49819919 | Extending survival by reducing sudden death with implantable cardioverter-defibrillators: a challenging clinical issue in non-ischaemic and ischaemic cardiomyopathies |
| Q33945130 | Facts and principles learned at the 32nd annual Williamsburg Conference on Heart Disease |
| Q37241690 | Failure to reassess ejection fraction after acute myocardial infarction in potential implantable cardioverter/defibrillator candidates: insights from the Translational Research Investigating Underlying disparities in acute Myocardial infarction Pati |
| Q47270854 | Final infarct size measured by cardiovascular magnetic resonance in patients with ST elevation myocardial infarction predicts long-term clinical outcome: an observational study |
| Q35995550 | Freedom from recurrent ventricular tachycardia after catheter ablation is associated with improved survival in patients with structural heart disease: An International VT Ablation Center Collaborative Group study. |
| Q39657207 | Frequency and Implications of Ischemia Prior to Ventricular Tachyarrhythmia in Patients Treated With a Wearable Cardioverter Defibrillator Following Myocardial Infarction |
| Q36843352 | Future directions of myocardial fatty acid imaging |
| Q38655221 | Health care utilisation after defibrillator implantation for primary prevention according to the guidelines in 2 Dutch academic medical centres |
| Q41493566 | Heart Rate Variability Density Analysis (Dyx) and Prediction of Long-Term Mortality after Acute Myocardial Infarction. |
| Q90622969 | Heart failure as a substrate and trigger for ventricular tachycardia |
| Q37969754 | Heart rate turbulence as risk-predictor after myocardial infarction |
| Q43055160 | Hotlines and clinical trial updates presented at the German Cardiac Society Meeting 2010: FAIR-HF, CIPAMI, LIPSIA-NSTEMI, Handheld-BNP, PEPCAD III, remote ischaemic conditioning, CERTIFY, PreSCD-II, German Myocardial Infarction Registry, DiaRegis |
| Q39037039 | How To Better Identify Patients That Do Not Benefit From Prophylactic ICD Therpy |
| Q83181413 | ICD Implantation in Patients With Ischemic Left Ventricular Dysfunction |
| Q50555961 | Identification of subpopulations with distinct treatment benefit rate using the Bayesian tree. |
| Q36247390 | Identifying the high risk patient with coronary artery disease--is ejection fraction all you need? |
| Q34069413 | Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial |
| Q33153560 | Impact of the multicenter automatic defibrillator implantation trial on clinical practice. |
| Q47298067 | Implantable Cardioverter-Defibrillators in Patients With a Continuous-Flow Left Ventricular Assist Device: An Analysis of the INTERMACS Registry. |
| Q33153984 | Implantable cardiac arrhythmia devices--Part II: implantable cardioverter defibrillators and implantable loop recorders. |
| Q89768490 | Implantable cardioverter defibrillator and cardiac resynchronization therapy use in New Zealand (ANZACS-QI 33) |
| Q40393364 | Implantable cardioverter defibrillator and survival after out-of-hospital cardiac arrest due to acute myocardial infarction in Denmark in the years 2001-2012, a nationwide study |
| Q38801619 | Implantable cardioverter defibrillator management: an update |
| Q37920404 | Implantable cardioverter defibrillators and cardiac resynchronisation therapy |
| Q37439059 | Implantable cardioverter defibrillators and their role in heart failure progression |
| Q36722100 | Implantable cardioverter defibrillators for prevention of sudden cardiac death |
| Q33770849 | Implantable cardioverter defibrillators for primary prevention of death in left ventricular dysfunction with and without ischaemic heart disease: a meta-analysis of 8567 patients in the 11 trials |
| Q36056217 | Implantable cardioverter defibrillators. Prophylactic use: an evidence-based analysis |
| Q37855663 | Implantable cardioverter-defibrillator implementation in acute heart failure syndromes: unanswered questions |
| Q35135663 | Implantable cardioverter-defibrillator therapy in patients with ventricular fibrillation out of hospital cardiac arrest secondary to acute coronary syndrome |
| Q30755342 | Implantable cardioverter-defibrillators for primary prevention of sudden cardiac death in CKD: a meta-analysis of patient-level data from 3 randomized trials |
| Q26852920 | Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations |
| Q36011885 | Implantable cardioverter-defibrillators: indications and unresolved issues. |
| Q35026178 | Implantable defibrillators for secondary prevention of sudden cardiac death in cardiac surgery patients with perioperative ventricular arrhythmias |
| Q36360167 | Implantable defibrillators with and without resynchronization for patients with left ventricular dysfunction |
| Q26829617 | Implantation-related complications of implantable cardioverter-defibrillators and cardiac resynchronization therapy devices: a systematic review of randomized clinical trials |
| Q37112689 | Improved Stratification of Autonomic Regulation for risk prediction in post-infarction patients with preserved left ventricular function (ISAR-Risk). |
| Q34354836 | Improved survival of patients with coronary artery disease and low ejection fraction with ICD implantation versus conventional therapy in a real world survey. |
| Q38692476 | Improvement of left ventricular ejection fraction in revascularized postmyocardial patients: indication for statistical fallacy |
| Q33994051 | Improvements in heart rate variability with exercise therapy |
| Q54714147 | In-hospital heart rate turbulence and microvolt T-wave alternans abnormalities for prediction of early life-threatening ventricular arrhythmia after acute myocardial infarction. |
| Q51248434 | Incidence and predictors of sudden cardiac death in patients with reduced left ventricular ejection fraction after myocardial infarction in an era of revascularisation. |
| Q43850545 | Incidence of sudden cardiac death after ventricular fibrillation complicating acute myocardial infarction: a 5-year cause-of-death analysis of the FAST-MI 2005 registry |
| Q45052440 | Indications and use of the wearable cardiac defibrillator |
| Q37390762 | Indications for ICD and cardiac resynchronization therapy for prevention of sudden cardiac death |
| Q36945243 | Indications for implantable cardioverter defibrillator use for primary prevention of sudden cardiac death |
| Q37902558 | Indications for implantable cardioverter-defibrillator placement in ischemic cardiomyopathy and after myocardial infarction. |
| Q36853736 | Inequitable distribution of implantable cardioverter defibrillators in Ontario |
| Q33582186 | Influence of healthy candidate bias in assessing clinical effectiveness for implantable cardioverter-defibrillators: cohort study of older patients with heart failure |
| Q39772445 | Interdisciplinary strategies for arrhythmia program development: measuring quality, performance, and outcomes. |
| Q38661446 | Introducing ICD-resistant mortality as an end point to evaluate the clinical efficacy of an implantable cardioverter-defibrillator in ischaemic cardiomyopathy. |
| Q90632447 | Is Time From Last Hospitalization for Heart Failure to Placement of a Primary Prevention Implantable Cardioverter-Defibrillator Associated With Patient Outcomes? |
| Q47606747 | Is there new hope for sudden cardiac death prevention early after myocardial infarction? |
| Q34492324 | Japan Implantable Devices in Coronary Artery Disease (JID-CAD) study design |
| Q93646494 | JournalScan |
| Q41686228 | Korean Guidelines for Diagnosis and Management of Chronic Heart Failure. |
| Q36141542 | Left Ventricular Dilatation Increases the Risk of Ventricular Arrhythmias in Patients With Reduced Systolic Function |
| Q42918733 | Left and right ventricular volumetry and ejection fraction with MRI: segmentation criteria and interobserver reproducibility |
| Q37832290 | Left ventricular ejection fraction for the risk stratification of sudden cardiac death: friend or foe? |
| Q42862038 | Letter by Dardas and Aaronson Regarding Article, “Impact of Implantable Cardioverter-Defibrillator, Amiodarone, and Placebo on the Mode of Death in Stable Patients With Heart Failure: Analysis From the Sudden Cardiac Death in Heart Failure Trial” |
| Q53595012 | Long-term benefit of first-line peri-implantable cardioverter-defibrillator implant ventricular tachycardia-substrate ablation in secondary prevention patients. |
| Q44659018 | Long-term follow-up of prophylactic implantable cardioverter-defibrillator-only therapy: comparison of ischemic and nonischemic heart disease |
| Q48196605 | Long-term use of the wearable cardioverter-defibrillator: prolonging life or prolonging indecision? |
| Q36147999 | Lower body mass index and atrial fibrillation as independent predictors for mortality in patients with implantable cardioverter defibrillator. |
| Q90599870 | Medical therapeutics: mortality effects, uncertainty, and informed consent |
| Q34728838 | Meta-analysis of catheter ablation as an adjunct to medical therapy for treatment of ventricular tachycardia in patients with structural heart disease |
| Q57446615 | Microvolt T-wave alternans and the selective use of implantable cardioverter defibrillators for primary prevention: A cost-effectiveness study |
| Q37889518 | Mineralocorticoid receptor antagonism: therapeutic potential in acute heart failure syndromes |
| Q38241365 | Molecular imaging to predict ventricular arrhythmia in heart failure |
| Q34585401 | Mortality and appropriate and inappropriate therapy in patients with ischaemic heart disease and implanted cardioverter-defibrillators for primary prevention: data from the Danish ICD Register |
| Q34194929 | Mortality benefits from implantable cardioverter-defibrillator therapy are not restricted to patients with remote myocardial infarction: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) |
| Q38600726 | Natural History and Implantable Cardioverter-Defibrillator Implantation After Revascularization for Stable Coronary Artery Disease With Depressed Ejection Fraction |
| Q51183806 | Near fatal arrhythmia induction by an implantable cardioverter defibrillator. |
| Q36383711 | New insights into cardiac resynchronization therapy. |
| Q37905685 | New paradigms in the prevention of sudden cardiac arrest and heart failure treatment |
| Q64115081 | Nine contemporary therapeutic directions in heart failure |
| Q24607930 | Non-evidence-based ICD implantations in the United States |
| Q40051788 | Non-invasive programmed stimulation to identify high-risk patients with implanted cardioverter defibrillator (the NIPS-ICD study): study protocol for a randomized controlled trial |
| Q61805960 | Non-ischemic cardiomyopathy in the elderly: A shocking conundrum |
| Q43967559 | Non-sustained ventricular tachycardia as a predictor of sudden cardiac death in patients with left ventricular dysfunction: a meta-analysis |
| Q37517247 | Noninvasive risk stratification after myocardial infarction: rationale, current evidence and the need for definitive trials |
| Q42553938 | Novel strategy to reduce sudden-death risk in the healing phase after myocardial infarction |
| Q36014154 | Optimising the dichotomy limit for left ventricular ejection fraction in selecting patients for defibrillator therapy after myocardial infarction |
| Q37067639 | Optimizing care of heart failure after acute MI with an aldosterone receptor antagonist |
| Q53556066 | Outcome of contemporary acute coronary syndrome complicated by ventricular tachyarrhythmias. |
| Q33940619 | Outcomes in African Americans undergoing cardioverter-defibrillator implantation for primary prevention of sudden cardiac death: findings from the Prospective Observational Study of Implantable Cardioverter-Defibrillators (PROSE-ICD). |
| Q33603090 | Outpatient treatment with the wearable cardioverter defibrillator: clinical experience in two Dutch centres |
| Q33158361 | Patient expectations from implantable defibrillators to prevent death in heart failure |
| Q49874615 | Patients with a wearable cardioverter-defibrillator (WCD) : Prescription, function and rehabilitation support |
| Q36859699 | Performance of 2014 NICE defibrillator implantation guidelines in heart failure risk stratification |
| Q38404916 | Peri-infarct zone pacing to prevent adverse left ventricular remodelling in patients with large myocardial infarction |
| Q61800117 | Polyscore of Non-invasive Cardiac Risk Factors |
| Q36383715 | Post myocardial infarction, left ventricular dysfunction, and the expanding role of cardiac implantable electrical devices |
| Q36351055 | Potential clinical impact of cardiovascular magnetic resonance assessment of ejection fraction on eligibility for cardioverter defibrillator implantation |
| Q36982439 | Practice viewpoints: AICD, who and when? |
| Q36861721 | Predicting Persistent Left Ventricular Dysfunction Following Myocardial Infarction: The PREDICTS Study |
| Q38660910 | Predicting appropriate shocks in patients with heart failure: Patient level meta-analysis from SCD-HeFT and MADIT II. |
| Q29040770 | Prediction of fatal or near-fatal cardiac arrhythmia events in patients with depressed left ventricular function after an acute myocardial infarction |
| Q93130452 | Prediction of mortality benefit based on periodic repolarisation dynamics in patients undergoing prophylactic implantation of a defibrillator: a prospective, controlled, multicentre cohort study |
| Q35122646 | Prediction of sudden cardiac death: next steps in pursuit of effective methodology |
| Q52584402 | Prediction of sudden death in elderly patients with heart failure. |
| Q51197361 | Prediction versus prevention of sudden cardiac death. |
| Q35252831 | Predictors of appropriate therapy in patients with implantable cardioverter-defibrillator for primary prevention of sudden cardiac death |
| Q34517911 | Predictors of implantable cardioverter-defibrillator use in patients with ischemic cardiomyopathy |
| Q39935776 | Predictors of sudden cardiac death change with time after myocardial infarction: results from the VALIANT trial |
| Q92685616 | Predictors of sudden cardiac death in high-risk patients following a myocardial infarction |
| Q35612100 | Prevalence and outcomes of patients receiving implantable cardioverter-defibrillators for primary prevention not based on guidelines |
| Q82440936 | Prevention of sudden cardiac death |
| Q38041468 | Prevention of sudden cardiac death in patients with chronic kidney disease: risk and benefits of the implantable cardioverter defibrillator |
| Q36057135 | Primary and secondary prevention of sudden cardiac death: who should get an ICD? |
| Q47133463 | Primary prevention implantable cardioverter defibrillator in patients with reduced ejection fraction: for ischemic or non-ischemic cardiomyopathy or both? |
| Q38542155 | Primary prevention of sudden cardiac death - Challenge the guidelines |
| Q37193184 | Primary prevention of sudden cardiac death using implantable cardioverter defibrillators |
| Q51362655 | Primary prevention of sudden cardiac death: a rational approach to the use of the implantable cardioverter defibrillator. |
| Q42119705 | Primary prevention with ICDs, are we on the right track? |
| Q38283800 | Prognostic implications of arrhythmias during primary percutaneous coronary interventions for ST-elevation myocardial infraction. |
| Q48709965 | Prognostic implications of left ventricular regional function heterogeneity assessed with two-dimensional speckle tracking in patients with ST-segment elevation myocardial infarction and depressed left ventricular ejection fraction |
| Q55028434 | Prognostic significance of nonsustained ventricular tachycardia in patients receiving cardiac resynchronization therapy for primary prevention: Analysis of the Japan cardiac device treatment registry database. |
| Q35706714 | Prognostic utility of T-wave alternans in a real-world population of patients with left ventricular dysfunction: the PREVENT-SCD study. |
| Q85525159 | Prognostic value of electromagnetic QRS fragmentation in survivors of sustained ventricular tachycardia or ventricular fibrillation compared with healthy controls |
| Q38880479 | Prognostic value of tissue Doppler imaging for predicting ventricular arrhythmias and cardiovascular mortality in ischaemic cardiomyopathy. |
| Q36666212 | Prophylactic catheter ablation for the prevention of defibrillator therapy |
| Q49588096 | Prophylactic use of the implantable cardioverter-defibrillator and its effect on the long-term survival, cardiovascular and sudden cardiac death in nonischemic cardiomyopathy patients-a systematic review and meta-analysis |
| Q35849384 | Real world effectiveness of primary implantable cardioverter defibrillators implanted during hospital admissions for exacerbation of heart failure or other acute co-morbidities: cohort study of older patients with heart failure |
| Q42982081 | Real world utilization and impact of the wearable cardioverter-defibrillator in a community setting |
| Q37821376 | Regenerative therapies in electrophysiology and pacing: introducing the next steps |
| Q34022396 | Relation between time from myocardial infarction to enrolment and patient outcomes in the Multicenter UnSustained Tachycardia Trial |
| Q36307927 | Relationship of the implantable cardioverter defibrillator and chronic resynchronization therapy: the perfect marriage? |
| Q34541882 | Relevance of guideline-based ICD indications to clinical practice |
| Q44707161 | Resuscitated cardiac arrest and prognosis following myocardial infarction |
| Q64122100 | Risk factors for sudden cardiac death to determine high risk patients in specific patient populations that may benefit from a wearable defibrillator |
| Q36440611 | Risk of death and recurrent ventricular arrhythmias in survivors of cardiac arrest concurrent with acute myocardial infarction. |
| Q33162850 | Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator |
| Q83014367 | Risk stratification for prevention of sudden cardiac death |
| Q37672333 | Risk stratification for sudden cardiac death: current approaches and predictive value |
| Q46954071 | Role of risk stratification after myocardial infarction |
| Q30240811 | Role of risk stratification and genetics in sudden cardiac death |
| Q57796671 | Role of the Wearable Defibrillator in Newly Diagnosed Heart Failure |
| Q38903885 | Roles and indications for use of implantable defibrillator and resynchronization therapy in the prevention of sudden cardiac death in heart failure |
| Q81356747 | SCD in patients with cardiomyopathy: use of microvolt T-wave alternans and other noninvasive tests for risk stratification and prevention of SCD |
| Q34224601 | Secondary prevention of atherosclerotic cardiovascular disease in older adults: a scientific statement from the American Heart Association |
| Q37582800 | Secondary prevention strategies for coronary heart disease |
| Q43048508 | Selection of patients for ICD therapy still under debate: Contra ICD. |
| Q41056093 | Severe ventricular arrhythmias in a patient with dilated cardiomyopathy and automated implantable defibrillator (AID) |
| Q42788492 | Should mechanical dyssynchrony be assessed in patients with implantable cardioverter-defibrillators? |
| Q43892315 | Single-chamber ICD, single-zone therapy in primary and secondary prevention patients: the simpler the better? |
| Q85092028 | Spatial vectorcardiogram to predict risk for sudden arrhythmic death: Phoenix risen from the ashes |
| Q35560103 | Strategies for the prevention and treatment of sudden cardiac death |
| Q92218779 | Sudden Cardiac Death Risk Stratification - An Update |
| Q87980772 | Sudden Cardiac Death: A Review Focused on Cardiovascular Imaging |
| Q92895866 | Sudden cardiac death after myocardial infarction |
| Q37981641 | Sudden cardiac death and implantable cardioverter defibrillators: two modern epidemics? |
| Q35028740 | Sudden cardiac death early after ST elevation myocardial infarction with and without severe left ventricular dysfunction |
| Q30433543 | Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop |
| Q35738748 | Sudden cardiac death risk stratification |
| Q45170638 | Sudden cardiac death unresponsive to implantable defibrillator therapy: an urgent target for clinicians, industry and government |
| Q38174217 | Sudden cardiac death: a critical appraisal of the implantable cardioverter defibrillator |
| Q36304357 | Sudden cardiac death: mechanisms, therapies and challenges |
| Q37317677 | Sudden death after myocardial infarction. |
| Q82598901 | Sudden death during follow-up after new-onset ventricular tachycardia in vascular surgery patients |
| Q38059618 | Surgical ventricular restoration for the treatment of heart failure |
| Q30589728 | Survival benefit of primary prevention implantable cardioverter-defibrillator therapy after myocardial infarction: does time to implant matter? A meta-analysis using patient-level data from 4 clinical trials |
| Q30891180 | Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials |
| Q51342942 | Testing each hypothesis marginally at alpha while still controlling FWER: how and when. |
| Q35539464 | The 7-year teesside experience of primary prevention ICD indications following primary PCI (PPCI) and the potential impact of a change in NICE guidance |
| Q40626713 | The Effect of Elapsed Time from Myocardial Infarction on Mortality and Major Adverse Cardiac and Cerebrovascular Events in ICD Patients |
| Q92618933 | The Limitations of Symptom-based Heart Failure Management |
| Q92646251 | The Role of the Cardioversion Defibrillator in Post Myocardial Infarction Sudden Cardiac Death: A Systematic Review of Clinical Trials and Observational Studies |
| Q38951636 | The Significance of Shocks in Implantable Cardioverter Defibrillator Recipients. |
| Q41260532 | The Wearable Cardioverter-Defibrillator (WCD) |
| Q90663958 | The Wearable Cardioverter-Defibrillator: Experience in 153 Patients and a Long-Term Follow-Up |
| Q28077810 | The Wearable Cardioverter/Defibrillator - Toy Or Tool? |
| Q33164931 | The clinical challenge of preventing sudden cardiac death immediately after acute ST-elevation myocardial infarction. |
| Q41019593 | The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most? |
| Q39318361 | The effects of gender on electrical therapies for the heart: physiology, epidemiology, and access to therapies: A report from the XII Congress of the Italian Association on Arrhythmology and Cardiostimulation (AIAC). |
| Q39315683 | The effects of gender on electrical therapies for the heart: procedural considerations, results and complications: A report from the XII Congress of the Italian Association on Arrhythmology and Cardiostimulation (AIAC). |
| Q38878487 | The evolution and benefit of device therapy in patients listed for heart transplant. |
| Q35642193 | The frequency and incremental cost of major complications among medicare beneficiaries receiving implantable cardioverter-defibrillators |
| Q51119109 | The impact of gender on survival amongst patients with implantable cardioverter defibrillators for primary prevention against sudden cardiac death. |
| Q38188016 | The influence of gender on heart rhythm disease. |
| Q37187583 | The relationship between glomerular filtration rate and survival in patients treated with an implantable cardioverter defibrillator |
| Q36158063 | The role of aldosterone blockade in patients with heart failure |
| Q37815453 | The role of cardiac electrophysiology in myocardial regenerative stem cell therapy |
| Q37057557 | The spectrum of epidemiology underlying sudden cardiac death |
| Q83978769 | The subcutaneous defibrillator will replace the transvenous defibrillator |
| Q84002974 | The terminal part of the QT interval (T peak to T end): a predictor of mortality after acute myocardial infarction |
| Q37994615 | The timing of implantable cardioverter-defibrillator implantation in patients with heart failure |
| Q38873501 | The wearable cardioverter defibrillator as a bridge to implantable defibrillator post myocardial infarction: what do we know? |
| Q38972235 | The wearable cardioverter-defibrillator: current technology and evolving indications |
| Q36796946 | Therapeutic and diagnostic role of electrical devices in acute heart failure. |
| Q36332860 | Therapies to prevent heart failure post-myocardial infarction |
| Q43252263 | Timing of eplerenone initiation and outcomes in patients with heart failure after acute myocardial infarction complicated by left ventricular systolic dysfunction: insights from the EPHESUS trial |
| Q34541818 | Tools for risk stratification of sudden cardiac death: a review of the literature in different patient populations |
| Q83141452 | Treating cardiac arrhythmias detected with an implantable cardiac monitor in patients after an acute myocardial infarction |
| Q40076747 | Treatment of ST-elevation myocardial infarction |
| Q42046045 | Treatment of heart failure with ACE inhibitors and beta-blockers: what is next? Aldosterone receptor antagonists? |
| Q36900790 | Treatment of ventricular dysrhythmias and sudden cardiac death: a guideline-based approach for patients with chronic left ventricular dysfunction |
| Q35122660 | Unmappable ventricular tachycardia after an old myocardial infarction. Long-term results of substrate modification in patients with an implantable cardioverter defibrillator |
| Q60928393 | Update on heart failure management and future directions |
| Q37587473 | Update on primary prevention implantable cardioverter-defibrillator therapy |
| Q36458785 | Use and Abuse of Internal Cardioverter Defibrillators for Primary Prevention |
| Q35669516 | Use of Implantable Cardioverter Defibrillators in Heart Failure Patients and Risk of Mortality: A Meta-Analysis |
| Q37963281 | Use of cardiac radionuclide imaging to identify patients at risk for arrhythmic sudden cardiac death |
| Q37818218 | Use of implantable cardioverter-defibrillators |
| Q38869631 | Use of the Wearable Cardioverter Defibrillator in High-Risk Populations |
| Q42231088 | Usefulness of a wearable cardioverter defibrillator combined with catheter ablation for ventricular tachyarrhythmia storms after a myocardial infarction: A case report |
| Q36146127 | Usefulness of the wearable cardioverter defibrillator in patients in the early post-myocardial infarction phase with high risk of sudden cardiac death: A single-center European experience |
| Q28067809 | Value of The Wearable Cardioverter Defibrillator (WCD) as a Bridging-Therapy before Implantation of a Cardioverter Defibrillator (ICD) |
| Q42363085 | Ventricular Arrhythmia after Acute Myocardial Infarction: 'The Perfect Storm' |
| Q36167677 | Ventricular arrhythmias: antiadrenergic therapy for the patient with coronary artery disease |
| Q38819031 | Ventricular fibrillation: triggers, mechanisms and therapies |
| Q82717797 | Ventricular tachycardia and sudden death after primary PCI-reperfusion therapy: impact on primary prevention of sudden cardiac death |
| Q37546146 | Ventricular tachycardia and ventricular fibrillation |
| Q83196237 | Ventricular tachycardia inducibility after radiofrequency ablation affects the outcomes in patients with coronary artery disease and implantable cardioverter-defibrillators: The role of left ventricular function |
| Q55291067 | Ventricular tachycardia-inducibility predicts arrhythmic events in post-myocardial infarction patients with low ejection fraction. A systematic review and meta-analysis. |
| Q91738902 | Wearable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death: A Systematic Review and Meta-Analysis |
| Q57068614 | Wearable Cardioverter-Defibrillator after Myocardial Infarction |
| Q33854130 | Wearable cardioverter defibrillator: Bridge or alternative to implantation? |
| Q37624451 | Wearable cardioverter defibrillator: a life vest till the life boat (ICD) arrives |
| Q41014024 | What an emergency physician needs to know about acute care of cardiac arrhythmias |
| Q33153973 | What are the professional and logistic demands to appropriately follow patients with an implantable cardioverter-defibrillator? |
| Q38622827 | When to consider an implantable cardioverter defibrillator following myocardial infarction? |
| Q58555805 | Who Benefits From a Defibrillator-Balancing the Risk of Sudden Versus Non-sudden Death |
| Q51108731 | Who should be treated with implantable cardioverter-defibrillators? |
| Q37641416 | Who should receive an implantable cardioverter-defibrillator after myocardial infarction? |
| Q36645676 | Why cardioverter-defibrillator implantation might not be the best idea for your elderly patient |
| Q53551288 | [A 65-year-old man with wearable cardioverter/defibrillator early after acute myocardial infarction]. |
| Q86846815 | [Device therapy of chronic heart failure: Update 2015] |
| Q79356295 | [Guidelines for the implantation of defibrillators] |
| Q89324597 | [ICD in elderly patients] |
| Q52903159 | [ICD therapy for primary prevention. The patient in the early post-infarct phase]. |
| Q84417230 | [ICD therapy for the primary prevention of sudden cardiac arrest. The patient after a myocardial infarction] |
| Q85290701 | [ICD therapy in the primary prevention of sudden cardiac death: Risk stratification and patient selection] |
| Q53771547 | [Indications for an implantable cardioverter/defibrillator]. |
| Q80307328 | [Prevention of sudden cardiac death] |
| Q84417233 | [The patient with chronic heart failure] |